XSpray Pharma AB (publ) Stock: price and insider trades · Sweden

XSpray Pharma AB (publ) belongs to the Health Care sector. Filings by its managers are published through Finansinspektionen. The last twelve months, up to 18 October 2026, brought 13 filings signed by 9 insiders.

On the market, 6 insiders bought (7 purchases totalling €203k) while 1 insider sold (1 sale totalling €60k). Netting one side against the other leaves €143k of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. At €61k, the purchase published on 15 June 2026 by Blake Leitch is the largest of the period. Among those who bought: 5 board members and 1 chief executive.

With 13 filings in twelve months, the company is more active than the median of 7 filings across the 886 companies we follow on the same exchange. Since 2025, the database holds 8 purchases and 1 sale by insiders of the company.

In the case of 5 purchases, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 29 September 2026, 18 days ago. Typically, a trade is published a median of 1 day after it takes place. Under the Market Abuse Regulation, managers have three business days to notify their trades.

For comparison within the same sector, see the insider buying recorded at MAIA Biotechnology, Inc. and Cooper Companies, Inc. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.